Further evidence for a common mechanism for shedding of cell surface proteins  by Müllberg, Jürgen et al.
FEBS 18086 FEBS Letters 401 (1997) 235-238 
Further evidence for a common mechanism for shedding of cell surface 
proteins 
Jürgen Müllberg*, Charles T. Rauch, Martin F. Wolfson, Beverly Castner, Jeffrey N. Fitzner, 
Carol Otten-Evans, Kendall M. Mohler, David Cosman, Roy A. Black 
Immunex Corporation, 51 University Street, Seattle, WA 98101, USA 
Received 29 November 1996 
Abstract Pro-TNFa, Steel factor, type IIIL-1R and IL-2Ra 
were expressed in COS-7 cells and the generation of their soluble 
forms was examined. The release of all four proteins was 
strongly stimulated by the phorbol ester PMA and completely 
blocked by a hydroxamate-based inhibitor of metalloproteases. 
COS-7 cell membranes were found to cleave various synthetic 
pro-TNFa peptides with the same specificity as a partially 
purified TNFot converting enzyme purified from human mono-
cytic cells, suggesting that the same enzyme may be responsible 
for at least some of the COS-7 cell shedding activity. 
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1. Introduction 
Soluble forms of many cytokine receptors and growth fac-
tors with membrane-bound precursors are generated by lim-
ited proteolysis of the membrane-associated protein; this 
process has been called shedding (for reviews see [1,2]). The 
structural requirements for shedding appear to vary. No con-
sensus amino acid sequence has been found at the proteolytic 
cleavage sites of cytokine receptor and growth factor precur-
sors identified so far [1,2]. It was demonstrated that the pres-
ence or absence of the cytoplasmic domains of the IL-6R [3] 
and the p60 TNFR [4] had no effect on shedding of these two 
proteins, whereas in the case of the p80 TNFR [5] the intra-
cellular part of the molecule influenced the generation of the 
soluble receptor. Furthermore it has been found that the C-
terminal valine residue of the cytoplasmic tail of TGFcc is 
critical for the release of this growth factor [6]. 
In contrast to the differences with respect to the structural 
requirements for shedding, the release of most soluble cyto-
kine receptors and growth factors is strongly enhanced by 
PMA (for reviews see [1,2]), a potent activator of protein 
kinase C [7,8], indicating that the underlying mechanisms 
are similar. Another line of evidence suggesting that the pro-
teolytic activities responsible for various shedding events are 
closely related comes from experiments with a hydroxamate-
based metalloprotease inhibitor we named TAPI (for 'TNFcc 
protease inhibitor'). This compound prevents the release of 
TNFcc from a monocytic cell line and protects mice against 
a lethal dose of endotoxin [9-11]. Interestingly, we found that 
TAPI also blocks shedding of the p80 TNFR from human T-
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cells [12] and shedding of the p60 TNFR and IL-6R from 
transfected cells and human primary monocytes [13]. A recent 
study demonstrated that TAPI blocks the release of L-selectin 
and TGFcc from transfected cells [14] and hydroxamates have 
also been shown to inhibit L-selectin shedding from primary 
cells [15-17]. Other proteins whose release is blocked by TAPI 
or related compounds include the thyrotropin receptor [18], 
Fas ligand [19], heparin-binding EGF-like growth factor [20] 
and angiotensin-converting enzyme [21]. No inhibitors other 
than hydroxamates have been found to prevent these shedding 
events under physiological conditions. 
Here we show that TAPI also inhibits shedding of Steel 
factor, type II IL-1R and IL-2Ra from transfected COS-7 
cells. In addition we demonstrate that the simian kidney cell 
line COS-7 and the human monocytic cell line THP1 possess 
metalloprotease activities with identical substrate specificity 
for pro-TNFa peptides. 
2. Materials and methods 
2.1. Reagents 
The metalloprotease inhibitor TAPI was prepared at Immunex Cor-
poration [9]. PMSF, leupeptin and pepstatin were obtained from 
Boehringer Mannheim (Indianapolis, IN). PMA was from Sigma 
(St. Louis, MO). [35S]Cysteine ( > 1000 Ci/mmol) and [35S]methionine 
(>1000 Ci/mmol) were purchased from Amersham (Arlington 
Heights, IL). The generation of expression vectors for murine Steel 
factor [22], the human type IIIL-1R [23] and the human IL-2Ra [24] 
was described previously. The cDNA containing the entire coding 
regions of the membrane-bound form of human TNFa was cloned 
into the mammalian expression plasmid pDC303 [25]. The prepara-
tion of a monoclonal antibody directed against the type IIIL-1R was 
previously described [26]. A rabbit antiserum specific for murine Steel 
factor was raised using murine recombinant Steel factor. A TNFR-Fc 
fusion protein was obtained as described [27]. 
2.2. Culture and transient transfection of COS-7 cells 
COS-7 cells were grown in DMEM/F12 (1:1) (Gibco-BRL, Grand 
Island, NY) containing 5% FCS (Intergen, Purchase, NJ), 50 U/ml 
penicillin and 50 μ^piιΐ streptomycin at 5% CO2 in a water saturated 
atmosphere. Transient transfections of COS-7 cells using DEAE/dex-
tran were performed as described [23]. After transfection cells were 
cultured for 48 h. The cells were metabolically labeled and stimulated 
under the conditions indicated in the figure legends. 
2.3. Immunoprecipitation of proteins 
COS-7 cells were metabolically labeled with [35S]cysteine/methio-
nine under the conditions indicated in the legend to Fig. 1. Culture 
supernatants were harvested and the cells were lysed in RIPA buffer 
(PBS containing 1% NP40, 1% 7-deoxycholic acid, 0.1% SDS) supple-
mented with protease inhibitors (EDTA, 10 mM; leupeptin, 0.5 μg/ 
ml; pepstatin, 0.7 μg/ml; PMSF, 35 μg/ml). To the culture media 
NP40 was added to a final concentration of 1%. Cell lysates and 
media were incubated with appropriate antibodies for 2 h at 4°C. 
In order to detect TNFa a TNFR-Fc fusion protein was used. Im-
munocomplexes were precipitated with protein A-Sepharose (Pharma-
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Fig. 1. Inhibition of shedding of TNFa (A), Steel factor (B) and type II IL-IR (C) in transfected COS-7 cells by TAPI. COS-7 cells (2X106 
cells) transiently transfected with cDNAs coding the membrane-bound forms of TNFa, Steel factor or type II IL-IR were metabohcally labeled 
with 50 \i.Ci of a mixture (1:1) of [35S]cysteine and [35S]methionine for 2 h in methionine/cysteine-free media. Cells were then incubated in me-
dia containing unlabeled methionine/cysteine for 1 h in the presence and the absence of PMA (10 ng/ml) and TAPI (200 μΜ) as indicated. 
TNFa, Steel factor and type II IL-IR proteins were immunoprecipitated from cell lysates and media using TNFR-Fc fusion protein (A) and 
antibodies specific for Steel factor (B) or type II IL-IR (C) and analyzed by SDS-PAGE and fluorography. Untransfected COS-7 cells were 
used as a control (lanes 1). 
cia, Piscataway, NJ) and separated on 8-16% SDS polyacrylamide 
gels (Novex, San Diego, CA) [28]. After treatment with fluorographic 
intensifier solution 'Amplify' (Amersham) gels were dried and exposed 
to X-ray film. 
2.4. ELISA for soluble IL-2Ra 
The levels of soluble IL-2Ra in culture media were determined 
using an ELISA kit purchased from Boehringer Mannheim following 
the manufacturer's instructions. 
2.5. Analysis of TNFa peptide digests 
Peptides were synthesized and digests were analyzed, by reverse 
phase HPLC, as previously described [29]. Digests were carried out 
in a volume of 20 μΐ, containing 0.5 mM peptide, 10 mM Tris-HCl 
(pH 8), 1% octylglucoside, for 4 h at 37°C. COS-7 cell membranes 
were prepared as previously described [9] and concentrated to 20 μg/ 
ml. TNFa converting enzyme (TACE) was prepared as previously 
described [9]. 
3. Results and discussion 
We assayed the release of TNFa, Steel factor, type II IL-IR 
and IL-2Ra from COS-7 cells transiently expressing the trans-
membrane forms of these proteins. As we reported previously 
[13], TNFa is shed from the transfected cells spontaneously 
and its release is strongly enhanced by PMA (Fig. 1A, lanes 2, 
3). The metalloprotease inhibitor TAPI prevents spontaneous 
shedding of TNFa (data not shown) as well as the PMA-
induced release of TNFa (Fig. 1A, lane 4). 
In the experiments shown in Fig. 1B,C, we investigated the 
influence of TAPI on shedding of Steel factor (Fig. IB) and 
type II IL-IR (Fig. 1C). In cell lysates, Steel factor is detected 
as a 45 kDa protein and the type II IL-IR as a 67 kDa 
protein; the corresponding soluble proteins migrate at appar-
ent molecular weights of 31 kDa and 55 kDa. In contrast to 
the release of TNFa, spontaneous shedding of both proteins 
occurs at a low level (lane 2). Shedding of Steel factor and 
type II IL-IR is strongly enhanced by PMA (lane 3), and this 
induced release is completely blocked by TAPI (lane 4). In the 
cell lysates of COS-7 cells expressing the type II IL-IR, a 
second immunoreactive protein with higher electrophoretic 
mobility was detected (Fig. 1C). This protein band may rep-
resent a biosynthetic precursor of the type II IL-IR which is 
not expressed at the cell surface, since its level is unaltered 
when cells are treated with PMA and TAPI. 
As shown in Fig. 2, TAPI also strongly inhibits the spon-
taneous and PMA-induced release of soluble IL-2Ra from 
COS-7 cells transfected with a cDNA coding the membrane-
bound protein. The level of soluble IL-2Ra detected in media 
of the transfected cells when cultured in the presence of TAPI 
was always about 20-25% of the amount in the untreated 
control. 
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Fig. 2. Inhibition of shedding of IL-2Ra in transfected COS-7 cells 
by TAPI. COS-7 cells (2X 106 cells) transfected with the cDNA cod-
ing the IL-2Ra were either treated for 1 h with PMA (10 ng/ml) in 
the absence (open triangle) or presence (filled triangle) of TAPI (200 
μΜ) or were cultured without PMA in absence (open circles) or 
presence (filled circles) of TAPI (200 μΜ) for the times indicated. 
The concentrations of soluble IL-2Ra in the culture media were de-
termined using a specific IL-2Ra ELISA. 
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Fig. 3. HPLC analysis of digests of TNFa peptides. Columns: I, Ac-SPLAQAVRSSSR-NH2; II, Ac-SPLAQFVRSSSR-NH2; III, Ac-SPLA-
QIVRSSSR-NH2. Rows: A, peptide incubated with buffer; B, COS-7 cell membranes incubated with buffer; C, peptide incubated with COS-7 
cell membranes; D, peptide incubated with TACE. The asterisks indicate the peptide substrates and the numbers indicate the products gener-
ated. The vertical axis represents relative absorbance, rather than specific units, because the absorbance of the three peptide substrates varied 
widely. 
To determine whether at least one of the shedding enzymes 
in COS-7 cells could be the TACE that we have partially 
purified from THP-1 cells [9], we compared the ability of 
COS-7 membranes and TACE to cleave a number of pro-
TNFa peptides. Both preparations generated the same prod-
ucts from a peptide representing the cleavage site in pro-
TNFoc (Fig. 3, column I), and both also generated the same 
products from an altered peptide in which Phe replaces the 
alanine N-terminal to the cleaved peptide bond (PI Ala resi-
due) (Fig. 3, column II). In all cases the observed peptide 
cleavage was sensitive to inhibition by TAPI (data not 
shown). Finally, both preparations failed to cleave a peptide 
in which He replaces the PI Ala residue (Fig. 3, column III). 
We have shown previously that the release of TNFa, 
TNFRs and IL-6R from transfected cells and human primary 
cells is inhibited by TAPI [12,13]. In this study we showed that 
TAPI also blocks the release of Steel factor, type IIIL-1R and 
IL-2Rcx from transfected COS-7 cells. The finding that the 
release of the soluble forms of all these molecules can be 
strongly accelerated by PMA ([5,13]; this study) and can be 
blocked by TAPI suggests that a common mechanism is in-
volved, possibly one (or a few) metalloprotease(s) with a 
broad substrate specificity. This view is also supported by 
results obtained with CHO cells and a mutant cell line defi-
cient in shedding of TGFa and ß-amyloid precursor protein 
[30]. The investigators found that many endogenous surface 
proteins on CHO cells are shed in response to PMA and that 
the mutant cell line failed to release any of these proteins. 
Alternatively, the existence of a family of metalloproteases, 
each responsible for shedding of a distinct membrane protein 
and sensitive to TAPI but not other metalloprotease inhibi-
tors, cannot be excluded. 
Our results suggest that the same enzyme that releases 
TNFa is present in both a simian kidney cell line and human 
monocytic cells. For TNFa, at least, there may be a single 
shedding mechanism. The biological function of shedding still 
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remains unclear. Many molecules which are generated by lim-
ited proteolysis such as soluble cytokine receptors and growth 
factors play important roles in certain biological systems [1,2]. 
On the other hand, the same stimuli may lead to the release of 
several surface proteins with various or even opposite func-
tions, e.g. the release of both TNFce and the two TNFRs 
(which might be able to neutralize TNF activity) from pri-
mary human cells can be stimulated by PMA. Since some 
spontaneous shedding activity is observed in cell lines such 
as COS-7 and THP1 cells, it is possible that shedding might 
be important for the transformation of cells. Shedding of cell 
surface molecules might allow tumor cells to escape detection 
by the immune system. 
Eventually the molecular cloning of individual shedding 
proteases and characterization of their substrate specificity 
will lead to a better understanding of their functions and 
also allow the rational design of specific inhibitors. 
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